News and Trends 15 Oct 2019 German Cancer Virotherapy Biotech Launches with €12M Series A …the arenavirus candidates that Abalos is developing will rely on the patient’s immune system to target cancer cells. According to the company, replication of its arenavirus candidates in the targeted… October 15, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Aqemia raises €30M for AI-enabled drug discovery pipeline …said its ambition is to optimize and accelerate early drug discovery projects on a massive scale in order to uncover dozens of proprietary new drug candidates. Those candidates will fuel… October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2022 Global Team-up Cuts Genomics Costs to Fight Salmonella Infections …mixed results in a phase I trial in 2002, and the program was dropped thereafter. There are now several ongoing programs; the most advanced candidate is in a phase I… February 10, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Sponsored by Lonza 9 Sep 2025 Advanced expression vector design to overcome challenges in developing multichain biotherapeutics …monoclonal antibodies, which have identical heavy chains (HCs) and light chains (LCs), multichain biotherapeutics can have three or four unique antibody or antibody-like polypeptide chains, so it is important to… September 9, 2025 - 8 minutesmins - By Jennifer Tsang Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2023 BioInvent receives funding for blood cancer treatments …antibody BI-1206, in non-Hodgkin’s lymphoma (NHL) and the anti-TNFR2 antibody BI-1808 in cutaneous T-cell lymphoma (CTCL). “We are delighted to conclude this agreement with the widely respected patient organization Leukemia… January 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017 Novartis Scores Major Phase III Win with New Cardiovascular Drug …in one of the largest and longest-running Phase III trials in the company’s history. Canakinumab is a fully human monoclonal antibody that inhibits IL-1ß, a key cytokine in the inflammatory… June 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2019 Top 10 Biotech Companies Leaving a Mark in Munich …biotech industry. MorphoSys Morphosys is one of just a few biotech companies in Europe valued at over €1Bn. Founded in 1992, the company specializes in the development of antibody treatments… November 4, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 UPDATE: FDA rejects Sanofi’s promising Rheumatoid Arthritis Drug …improvement in physical function of patient joints. There is a strong competition for antibody research into chronic auto-immune diseases such as Rheumatoid. A few Biotech giants are extra anxious to… October 31, 2016 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
In Depth 2 Jan 2018 The Labiotech Dictionary of Important Biotech Terms …up to the immune system for destruction. The structure of an antibody, which allows it to bind dangerous pathogens, fight infection and stimulate an immune response. Some of Europe’s best… January 2, 2018 - 14 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Marengo advancing its lead TCR activator into clinic after FDA clearance …a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical studies. Marengo Therapeutics plans to… September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment …who will respond best to the drug. No financial details of the deal were disclosed. ADC Therapeutics’ drug is an antibody that is chemically joined to a molecule that kills… August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jan 2023 EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease …beta (Aβ) protofibril antibody, for the treatment of early Alzheimer’s disease (mild cognitive impairment due to Alzheimer’s disease (AD) and mild AD dementia) with confirmed amyloid pathology, for review following… January 27, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email